Related Experiment Video
Updated: May 10, 2026
10:49
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
[Update on L-asparaginase treatment in paediatrics]
C Moscardó Guilleme1, R Fernández Delgado, J Sevilla Navarro
1Hospital General Universitario, Alicante, España.
Anales De Pediatria (Barcelona, Spain : 2003)
|June 4, 2013
Summary
L-asparaginase (L-ASP) is crucial for treating leukemia and lymphoma by depleting L-asparagine. Current formulations vary in efficacy and side effects, prompting research into improved L-ASP delivery methods.
Area of Science:
- Biochemistry
- Oncology
- Pharmacology
Context:
- L-asparaginase (L-ASP) is a vital chemotherapeutic enzyme used in treating acute lymphoblastic leukemia and non-Hodgkin lymphoma.
- It functions by depleting L-asparagine, essential for lymphoblast survival, thereby inducing apoptosis.
Purpose:
- This review evaluates the dosage, activity, and side effects of three L-ASP formulations: native Escherichia coli L-ASP, pegylated E. coli L-ASP, and Erwinia chrysanthemi L-ASP (Erwinia ASP).
- It aims to address ongoing debates regarding L-ASP use and its associated toxicities.
Summary:
- Differences exist among L-ASP formulations, impacting patient quality of life due to short half-lives and frequent intramuscular injections.
- Alternative formulations, including longer-acting pegylated L-ASP and intravenous options, show promising results.
Impact:
- Further research is necessary to determine optimal L-ASP formulations, routes of administration, dosing, and adverse effect management.
- Establishing best practices will enhance therapeutic outcomes and patient well-being in hematologic malignancies.
Keywords:
Acute Lymphoblastic LeukemiaAsparaginaseAsparraginasaAsparraginasa de Erwinia: asparraginasa de Escherichia coli pegiladaAsparraginasa de Escherichia coli nativaErwinia AsparaginaseEscherichia coli AsparaginaseHodgkin lymphomaLeucemia linfoblástica agudaLinfoma de HodgkinPegylated AsparaginaseRelated Concept Videos
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
01:28Acute Pyelonephritis II: Diagnostic Studies and Management
Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
01:26Pharmaceutical Poisoning: Treatment Strategies
Treatment strategies for poisoning are a critical aspect of emergency medicine, focusing on preventing the absorption of toxins and enhancing their elimination. When a poisoning incident occurs, the first response is to halt exposure and decontaminate the patient, particularly through gastrointestinal (GI) methods if the poison was ingested.Gastrointestinal Decontamination Techniques:Activated charcoal is the cornerstone of GI decontamination. It works through adsorption, binding the toxin to...